The Platelet Lifeline to Cancer: Challenges and Opportunities.

Abstract:

:Besides their function in limiting blood loss and promoting wound healing, experimental evidence has highlighted platelets as active players in all steps of tumorigenesis including tumor growth, tumor cell extravasation, and metastasis. Additionally, thrombocytosis in cancer patients is associated with adverse patient survival. Due to the secretion of large amounts of microparticles and exosomes, platelets are well positioned to coordinate both local and distant tumor-host crosstalk. Here, we present a review of recent discoveries in the field of platelet biology and the role of platelets in cancer progression as well as challenges in targeting platelets for cancer treatment.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Haemmerle M,Stone RL,Menter DG,Afshar-Kharghan V,Sood AK

doi

10.1016/j.ccell.2018.03.002

subject

Has Abstract

pub_date

2018-06-11 00:00:00

pages

965-983

issue

6

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(18)30070-9

journal_volume

33

pub_type

杂志文章,评审
  • Turning on a dimer: new insights into MLL chimeras.

    abstract::In this issue of Cancer Cell, demonstrate a novel mechanism for the oncogenic activity of MLL chimeric proteins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a platform for MLL homodimerization, allowing recruitment of accessory factors needed to activa...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/s1535-6108(03)00192-2

    authors: Hsu K,Look AT

    更新日期:2003-08-01 00:00:00

  • Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

    abstract::In mice, Lkb1 deletion and activation of Kras(G12D) results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lk...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2010.04.026

    authors: Carretero J,Shimamura T,Rikova K,Jackson AL,Wilkerson MD,Borgman CL,Buttarazzi MS,Sanofsky BA,McNamara KL,Brandstetter KA,Walton ZE,Gu TL,Silva JC,Crosby K,Shapiro GI,Maira SM,Ji H,Castrillon DH,Kim CF,García-Echeve

    更新日期:2010-06-15 00:00:00

  • Advancing the field of drug delivery: taking aim at cancer.

    abstract::Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(03)00276-9

    authors: Moses MA,Brem H,Langer R

    更新日期:2003-11-01 00:00:00

  • Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

    abstract::Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2012.11.014

    authors: Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

    更新日期:2013-01-14 00:00:00

  • Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

    abstract::We show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. Critically, because RAS is activated by BCR-ABL, in drug-resistant chronic myeloid leukemia (CML) cells, RAS activity persists in the pre...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.11.004

    authors: Packer LM,Rana S,Hayward R,O'Hare T,Eide CA,Rebocho A,Heidorn S,Zabriskie MS,Niculescu-Duvaz I,Druker BJ,Springer C,Marais R

    更新日期:2011-12-13 00:00:00

  • The RB and p53 pathways in cancer.

    abstract::The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) a...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(02)00102-2

    authors: Sherr CJ,McCormick F

    更新日期:2002-08-01 00:00:00

  • Wnt breakers in colon cancer.

    abstract::Beta-catenin and Tcf4 are the downstream effectors of the Wnt signaling cascade. In colorectal cancer, mutations in Wnt cascade genes such as APC lead to the inappropriate formation of beta-catenin/Tcf4 complexes. Earlier work has predicted that disruption of the beta-catenin/Tcf4 protein-protein interaction could rev...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章,评审

    doi:10.1016/s1535-6108(03)00339-8

    authors: Clevers H

    更新日期:2004-01-01 00:00:00

  • Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

    abstract::Immune checkpoint blockade therapies fail to induce responses in the majority of cancer patients, so how to increase the objective response rate becomes an urgent challenge. Here, we demonstrate that sufficient T cell infiltration in tumor tissues is a prerequisite for response to PD-L1 blockade. Targeting tumors with...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.02.004

    authors: Tang H,Wang Y,Chlewicki LK,Zhang Y,Guo J,Liang W,Wang J,Wang X,Fu YX

    更新日期:2016-03-14 00:00:00

  • The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

    abstract::Tumors constitute highly suppressive microenvironments in which infiltrating T cells are "exhausted" by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor and other CD8(+) T cell-dependent chronic immune responses. TIGIT is highly expressed on human an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2014.10.018

    authors: Johnston RJ,Comps-Agrar L,Hackney J,Yu X,Huseni M,Yang Y,Park S,Javinal V,Chiu H,Irving B,Eaton DL,Grogan JL

    更新日期:2014-12-08 00:00:00

  • EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

    abstract::The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific bind...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.07.006

    authors: Béguelin W,Teater M,Gearhart MD,Calvo Fernández MT,Goldstein RL,Cárdenas MG,Hatzi K,Rosen M,Shen H,Corcoran CM,Hamline MY,Gascoyne RD,Levine RL,Abdel-Wahab O,Licht JD,Shaknovich R,Elemento O,Bardwell VJ,Melnick AM

    更新日期:2016-08-08 00:00:00

  • Targeting the Residual Leukemia Cells after Chemotherapy.

    abstract::One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML r...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2018.08.012

    authors: Vu LP,Kharas MG

    更新日期:2018-09-10 00:00:00

  • Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.

    abstract::Slit is a secreted protein known to function through the Roundabout (Robo) receptor as a chemorepellent in axon guidance and neuronal migration, and as an inhibitor in leukocyte chemotaxis. Here we show Slit2 expression in a large number of solid tumors and Robo1 expression in vascular endothelial cells. Recombinant S...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(03)00164-8

    authors: Wang B,Xiao Y,Ding BB,Zhang N,Yuan Xb,Gui L,Qian KX,Duan S,Chen Z,Rao Y,Geng JG

    更新日期:2003-07-01 00:00:00

  • The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

    abstract::The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest. This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor ...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/j.ccr.2008.06.001

    authors: Bernassola F,Karin M,Ciechanover A,Melino G

    更新日期:2008-07-08 00:00:00

  • Impact of COVID-19 Pandemic on Cancer Research.

    abstract::The COVID-19 pandemic is profoundly changing cancer researchers and cancer research. Leaders from different fields and at different career stages share their perspectives. ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.10.007

    authors: Zon L,Gomes AP,Cance WG,Ribas A,Tuveson D,Postel-Vinay S,Massard C,Barlési F

    更新日期:2020-11-09 00:00:00

  • BRAF inhibitor unveils its potential against advanced melanoma.

    abstract::Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 tha...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.10.001

    authors: Vultur A,Villanueva J,Herlyn M

    更新日期:2010-10-19 00:00:00

  • Proteogenomic Characterization of Human Early-Onset Gastric Cancer.

    abstract::We report proteogenomic analysis of diffuse gastric cancers (GCs) in young populations. Phosphoproteome data elucidated signaling pathways associated with somatic mutations based on mutation-phosphorylation correlations. Moreover, correlations between mRNA and protein abundances provided potential oncogenes and tumor ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.12.003

    authors: Mun DG,Bhin J,Kim S,Kim H,Jung JH,Jung Y,Jang YE,Park JM,Kim H,Jung Y,Lee H,Bae J,Back S,Kim SJ,Kim J,Park H,Li H,Hwang KB,Park YS,Yook JH,Kim BS,Kwon SY,Ryu SW,Park DY,Jeon TY,Kim DH,Lee JH,Han SU,

    更新日期:2019-01-14 00:00:00

  • Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma.

    abstract::Although high c-Myc protein expression is observed alongside MYC amplification in some cancers, in most cases protein overexpression occurs in the absence of gene amplification, e.g., T cell lymphoma (TCL). Here, Ca2+/calmodulin-dependent protein kinase II γ (CAMKIIγ) was shown to stabilize the c-Myc protein by direct...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2017.06.001

    authors: Gu Y,Zhang J,Ma X,Kim BW,Wang H,Li J,Pan Y,Xu Y,Ding L,Yang L,Guo C,Wu X,Wu J,Wu K,Gan X,Li G,Li L,Forman SJ,Chan WC,Xu R,Huang W

    更新日期:2017-07-10 00:00:00

  • Cancer Patients and Risk of Mortality for COVID-19.

    abstract::Two recent Lancet and Lancet Oncology papers report that cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have higher mortality rates. Common independent factors associated with increased risk of death were older age, history of smoking status, number of comorbidities, more a...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2020.07.006

    authors: Curigliano G

    更新日期:2020-08-10 00:00:00

  • Opening a new GATAway for treating KRAS-driven lung tumors.

    abstract::In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2012.04.032

    authors: Barbacid M

    更新日期:2012-05-15 00:00:00

  • Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability.

    abstract::In this study, we show that the formation of polyploidy following sustained mitotic checkpoint activation appears to be preceded by the ubiquitin-dependent proteolysis of hBubR1. In addition, the level of hBubR1 is significantly reduced not only in polyploid cells created by sustained mitotic spindle damage, but also ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(03)00302-7

    authors: Shin HJ,Baek KH,Jeon AH,Park MT,Lee SJ,Kang CM,Lee HS,Yoo SH,Chung DH,Sung YC,McKeon F,Lee CW

    更新日期:2003-12-01 00:00:00

  • Deubiquitination and Stabilization of PD-L1 by CSN5.

    abstract::Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.10.010

    authors: Lim SO,Li CW,Xia W,Cha JH,Chan LC,Wu Y,Chang SS,Lin WC,Hsu JM,Hsu YH,Kim T,Chang WC,Hsu JL,Yamaguchi H,Ding Q,Wang Y,Yang Y,Chen CH,Sahin AA,Yu D,Hortobagyi GN,Hung MC

    更新日期:2016-12-12 00:00:00

  • The Two Faces of NF-κB Signaling in Cancer Development and Therapy.

    abstract::Constitutive activation of NF-κB signaling can promote oncogenesis, providing a rationale for anticancer strategies that inhibit NF-κB signaling. Two recent publications in Genes & Development provide evidence that, in contexts where prosurvival signals derive from other oncogenes, NF-κB activity instead enhances sens...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2011.10.026

    authors: Klein U,Ghosh S

    更新日期:2011-11-15 00:00:00

  • Cancer's sweet tooth.

    abstract::Even in the presence of an adequate oxygen supply, many tumors metabolize the majority of the glucose they take up through glycolysis. It has been a long-held belief that this glycolytic phenotype is due to cancer-specific defects in mitochondrial oxidative phosphorylation. In this issue of Cancer Cell, Fantin et al. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2006.05.012

    authors: Bui T,Thompson CB

    更新日期:2006-06-01 00:00:00

  • Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases.

    abstract::Deregulation of growth factor receptor tyrosine kinases (RTKs) is linked to a large number of malignancies. This occurs through a variety of mechanisms that result in enhanced activity of the receptor. Considerable evidence now supports the idea that loss of negative regulation plays an important role in receptor dere...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/s1535-6108(03)00136-3

    authors: Peschard P,Park M

    更新日期:2003-06-01 00:00:00

  • Wild-type RAS: keeping mutant RAS in CHK.

    abstract::Mutant RAS-driven tumorigenesis was thought for decades to arise independently of wild-type RAS isoforms, but recent evidence indicates wild-type isoforms are involved. In this issue of Cancer Cell, Grabocka and colleagues report how the loss of wild-type RAS alters oncogenic signaling and dampens the DNA-damage respo...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2014.01.029

    authors: Anastassiadis T,Brown EJ

    更新日期:2014-02-10 00:00:00

  • Sumoylation pathway is required to maintain the basal breast cancer subtype.

    abstract::The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2014.04.008

    authors: Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

    更新日期:2014-06-16 00:00:00

  • The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.

    abstract::Gankyrin is an ankyrin repeat oncoprotein commonly overexpressed in hepatocellular carcinomas. Gankyrin interacts with the S6 proteasomal ATPase and accelerates the degradation of the tumor suppressor Rb. We show here that gankyrin has an antiapoptotic activity in cells exposed to DNA damaging agents. Downregulation o...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.06.006

    authors: Higashitsuji H,Higashitsuji H,Itoh K,Sakurai T,Nagao T,Sumitomo Y,Masuda T,Dawson S,Shimada Y,Mayer RJ,Fujita J

    更新日期:2005-07-01 00:00:00

  • Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

    abstract::Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials. Here we report that angiogenesis inhibitors targeting the VEGF pathway demonstrate antitumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitant...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2009.01.027

    authors: Pàez-Ribes M,Allen E,Hudock J,Takeda T,Okuyama H,Viñals F,Inoue M,Bergers G,Hanahan D,Casanovas O

    更新日期:2009-03-03 00:00:00

  • Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.

    abstract::The link between GBM molecular subtype and response to treatment remains undefined. In this issue of Cancer Cell, Cosset and colleagues define a subpopulation of patients within the proneural/classical subtype sensitive to integrin blockade because of a Glut3 addiction. These findings reveal context-dependent druggabl...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.11.017

    authors: Bunda S,Zadeh G,Aldape KD

    更新日期:2017-12-11 00:00:00

  • RalGDS is required for tumor formation in a model of skin carcinogenesis.

    abstract::To investigate the role of signaling by the small GTPase Ral, we have generated mice deficient for RalGDS, a guanine nucleotide exchange factor that activates Ral. We show that RalGDS is dispensable for mouse development but plays a substantial role in Ras-induced oncogenesis. Lack of RalGDS results in reduced tumor i...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.01.029

    authors: González-García A,Pritchard CA,Paterson HF,Mavria G,Stamp G,Marshall CJ

    更新日期:2005-03-01 00:00:00